arimoclomol (Miplyffa)
Jump to navigation
Jump to search
Indications
Dosage
- oral capsules for use in combination with enzyme inhibitor miglustat
- 47-124 mg adminstered TID depending upon weight
Adverse effects
- increase in serum creatinine of 10-20%
- most common adverse events in trials
Mechanism of action
- unknown
More general terms
References
- ↑ Lou N First Drug Approved for Niemann-Pick Disease Type C. Arimoclomol (Miplyffa) greenlit for ultra-rare genetic disorder. MedPage Today September 20, 2024 https://www.medpagetoday.com/genetics/generalgenetics/112052
Database
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=9568077
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=208924
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=10358237
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=53427024
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=9818287
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6507255
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=92461203